Towards the Integration of an Anti-Contractile Compound Within Drug-Coated Balloon Therapy
Cardiovascular Engineering and Technology · 2025
DOI: 10.1007/s13239-025-00798-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Engineering and Technology, 2025. Verfasst von Dima BaniHani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, College of Engineering and Computing, University of South Carolina, Columbia, SC, 29208, USA. Hauptthemen laut MEDLINE: Paclitaxel, Angioplasty, Balloon, Muscle, Smooth, Vascular, Peripheral Arterial Disease. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, BLRD VA, NIDDK NIH HHS.
Abstract (Originalsprache)
Purpose
Drug-coated balloon (DCB) therapy is a promising approach to treat peripheral artery disease (PAD), wherein lesion site preparation, balloon inflation, and the local delivery of anti-proliferative drugs such as paclitaxel (PTX) restores and retains lumen patency. Although largely successful in PAD applications, broader clinical deployment is in part limited by the occurrence of late lumen loss due to inward vessel remodeling at the treatment site, a maladaptive chronic response that has been clinically-observed to coincide with elevations in resident vascular smooth muscle cell (vSMC) tone. This study aims to explore a novel strategy to improve DCB efficacy via drug-based attenuation of vSMC tone at the treatment site.
Methods
As a strategy to mitigate this post-DCB failure mode, we consider the local co-delivery of PTX and an additional drug that induces relaxation of vSMCs, specifically the clinically-approved anti-hypertensive drug valsartan (VAL). The potential benefit of drug-based regulation of vSMC tone is supported by recent theoretical studies that predict inward remodeling in the presence of hypertension and endothelial cell dysfunction, both common co-morbidities in PAD patients and established causes of elevated vSMC contractility. The specific selection of VAL as the anti-contractile payload constituent is motivated by its well-known pharmacokinetic and safety profiles, and the notion that current clinical use and familiarity could promote rapid translation in the context of DCBs.
Results
Our obtained results quantify the potency of VAL to induce local vSMC relaxation in arterial tissue, demonstrate the feasibility of PTX and VAL co-delivery using the canonical excipient urea for balloon coating formation, and elucidate key structure-function relations to facilitate efficient drug delivery with these novel coatings.
Conclusion
Our study supports the continued evaluation of VAL for inclusion in DCB formulations due to its potential to redirect post-treatment arterial remodeling. Future in-vivo studies which examine the co-delivery of PTX and VAL in the context of DCBs are needed to establish both the safety and efficacy of this novel approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, College of Engineering and Computing, University of South Carolina, Columbia, SC, 29208, USA.
- Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, 19104, USA.
- Columbia VA Health Care Center, VA, Columbia, SC, 29208, USA.
- Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC, 29208, USA.
- Center of Cross-Organ Vascular Pathology, Department of Medicine, Boston University School of Medicine, Boston, MA, 02118, USA.
- VA Boston Healthcare System, Boston, MA, 02115, USA.
Förderung
- NHLBI NIH HHS
- BLRD VA
- NIDDK NIH HHS
- NIGMS NIH HHS
- University of South Carolina
Zitieren
APA
BaniHani, D., Eberth, J. F., Spinale, F. G., Chitalia, V. C., Ferdous, J., Kolachalama, V. B., & Shazly, T. (2025). Towards the Integration of an Anti-Contractile Compound Within Drug-Coated Balloon Therapy. Cardiovascular Engineering and Technology. https://doi.org/10.1007/s13239-025-00798-7
Vancouver
BaniHani D, Eberth JF, Spinale FG, Chitalia VC, Ferdous J, Kolachalama VB, et al. Towards the Integration of an Anti-Contractile Compound Within Drug-Coated Balloon Therapy. Cardiovascular Engineering and Technology. 2025. doi:10.1007/s13239-025-00798-7
BibTeX
@article{BaniHani2025,
author = {BaniHani, Dima and Eberth, John F and Spinale, Francis G and Chitalia, Vipul C and Ferdous, Jahid and Kolachalama, Vijaya B and Shazly, Tarek},
title = {Towards the Integration of an Anti-Contractile Compound Within Drug-Coated Balloon Therapy},
journal = {Cardiovascular Engineering and Technology},
year = {2025},
doi = {10.1007/s13239-025-00798-7}
}
EUVIMED